• Home
  • HCN Trends
  • Contact Us

Search Articles

Cardiology Covid-19 Dermatology Endocrinology General Interest Hematology Infectious Disease Neurology Oncology Pediatrics Psychiatry Pulmonology Rheumatology Surgery Uncategorized
acetaminophen actemra adverse events anemia antibody anxiety azithromycin bipolar disorder bleeding blog brain tumor breast cancer burnout Cancer capecitabine capmatinib cervical cancer chloroquine chronic pain clinical trials cloroquine CME compensation coronary artery disease coronavirus cost covid-19 death diagnosis doctors dosing drug interactions efficacy erlotinib exercise FDA/regulation fever filters glioblastoma green tea guidelines hemophilia hiv hospital hydroxychloroquine ibrutinib ibuprofen immunity induction chemotherapy infectious disease influenza ipilimumab irinotecan iron-deficiency anemia isn letrozole leukemia Lung cancer malaria mask Masks mbc MDS medical cannabis medical school Medicine mesothelioma metastatic colorectal cancer Myelodysplastic Syndromes myeloid leukemia nivolumab nsclc olaparib osimertinib outcomes pandemic patient safety patients pediatrics perjeta physicians podcast practice practice management prevention procedure prostate cancer radiation remdesivir research/studies respirators respiratory retevmo rucaparib sars SCLC selinexor selpercatinib sorafenib stroke Survival/Mortality symptoms syndrome telemedicine testing therapy thrombosis thyroid cancer time tnbc tocilizumab trastuzumab treatment vaccine venetoclax xpovio

Tag: nivolumab

HMP CommunicationsFDA Approves Nivolumab for Treatment of Certain Patients With ESCC

Based on the data from the ATTRACTION-3 clinical trial, the FDA approved nivolumab (Opdivo; BMS) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who previously received fluoropyrimidine- and platinum-based chemotherapy.

treatmentFDA/regulationnivolumab

American Medical AssociationEffect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma

In this Original Investigation, JAMA Oncology explores the CheckMate 143 Phase 3 trial, asking whether PD-1 immune checkpoint inhibition with nivolumab improves overall survival compared with bevacizumab treatment for patients with recurrent glioblastoma.

glioblastomanivolumabtreatment
  • © Healthcare Communications Network
  • Privacy Policy